Annual report pursuant to Section 13 and 15(d)

Fair Value Measurements (Tables)

v3.8.0.1
Fair Value Measurements (Tables)
 12 Months Ended
Dec. 31, 2017
Fair Value Disclosures [Abstract]  
Schedule of Financial Instrument Measured on Recurring Basis

The valuation methodologies used for the Company’s financial instruments measured on a recurring basis at fair value, including the general classification of such instruments pursuant to the valuation hierarchy, is set forth in the tables below.

 

    As of December 31, 2017     Fair Value Measurements  
    Carrying     Fair     As of December 31, 2017  
    Amount     Value     Level 1     Level 2     Level 3  
Liabilities:                                        
Contingent consideration:                                        
Asuragen   $ 1,581     $ 1,581     $ -     $ -     $ 1,581  
Other long-term liabilities:                                        
Warrant liability     473       473       -       -       473  
    $ 2,054     $ 2,054     $ -     $ -     $ 2,054  

 

    As of December 31, 2016     Fair Value Measurements  
    Carrying     Fair     As of December 31, 2016  
    Amount     Value     Level 1     Level 2     Level 3  
Liabilities:                                        
Contingent consideration:                                        
Asuragen   $ 1,545     $ 1,545     $ -     $ -     $ 1,545  
RedPath     5,969       5,969       -       -       5,969  
    $ 7,514     $ 7,514     $ -     $ -     $ 7,514  

Schedule of Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation

The Pre-Funded Warrants were fully exercised in 2017 and therefore the Company has no remaining liability associated with those warrants.

 

                            Cancellation     Adjustment        
                            of Obligation/     to Fair Value/        
    December 31, 2016     Initial Liability     Payments (1)     Accretion     Conversions Exercises     Mark to Market     December 31, 2017  
Contingent consideration:                                                        
Asuragen   $ 1,545             $ (260 )   $ 122     $ -     $ 174     $ 1,581  
Redpath     5,969               -       -       (5,969 )     -       -  
Embedded conversion option     -       208       -       -       (269 )     61       -  
Pre-Funded Warrants     -       2,247       -       -       (2,337 )     90       -  
Underwriters Warrants     -       422       -       -       -       51       473  
    $ 7,514     $ 2,877     $ (260 )   $ 122     $ (8,575 )   $ 376     $ 2,054  

 

  (1) Royalty payments of $235,000 are reflected within Cash Flows from Operations. The remaining $25,000 represents a milestone payment related to financing the Asuragen acquisition and is reflected in Cash Flows from Financing Activities.